CRC Research Update — June 30, 2026
Today's colorectal cancer research highlights
lynch-syndrome
A collection of 50 issues
CRC Research Update — June 20, 2026
Today's colorectal cancer research highlights
Lynch syndrome prevalence varies by population and cancer type
Skip to content
The CRC Digest
Lynch syndrome prevalence varies by population and cancer type
A review of published studies found Lynch syndrome prevalence ranges from 0.7% to 4% among unselected colorectal cancer patients, with higher rates in selected high-risk patients and up to 5.9% in Canadian endometrial
Immunotherapy transforms surgical decisions in Lynch syndrome CRC
Skip to content
The CRC Digest
Immunotherapy transforms surgical decisions in Lynch syndrome CRC
Narrative review examines how immune checkpoint inhibitors achieving 60-100% pathological complete response rates in MSI-H/dMMR CRC are challenging traditional recommendations for extensive prophylactic surgery in Lynch syndrome patients. (European Journal of Surgical Oncology)
This content
CRC Research Update — June 06, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 04, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 13, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 12, 2026
Today's colorectal cancer research highlights
Five Decades of Familial Adenomatous Polyposis Surveillance in Denmark
Skip to content
The CRC Digest
Five Decades of Familial Adenomatous Polyposis Surveillance in Denmark
A study from the Danish Polyposis Register emphasizes the importance of lifelong endoscopic surveillance and tailored treatment strategies for FAP patients, who face elevated risks for duodenal and pancreatic cancers even after colectomy. (APMIS)
This
Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers
Skip to content
The CRC Digest
Nous-209 Immunotherapy Targets Appear Early in Lynch Syndrome Precancers
In a study of Lynch syndrome carriers, 83% of advanced adenomas and 58% of adenomas were mismatch repair-deficient, and the presence of Nous-209 mutations correlated strongly with microsatellite instability status, suggesting potential for preventive immunotherapy.